Explore
Trendline
Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success
Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success
Read More
Trendline
Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress
Citius Oncology Secures $36.5 Million Financing Amid LYMPHIR Launch Progress
Read More
Trendline
Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments
Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments
Read More
Trendline
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026
Read More
Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Read More
Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Read More
Trendline
Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress
Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress
Read More
Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Read More
Trendline
Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion
Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion
Read More
Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Read More
Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Read More
Trendline
Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026
Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026
Read More
